These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1436 related articles for article (PubMed ID: 26784587)
21. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798 [TBL] [Abstract][Full Text] [Related]
22. Hyaluronate tethered, "smart" multiwalled carbon nanotubes for tumor-targeted delivery of doxorubicin. Datir SR; Das M; Singh RP; Jain S Bioconjug Chem; 2012 Nov; 23(11):2201-13. PubMed ID: 23039830 [TBL] [Abstract][Full Text] [Related]
23. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index. Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964 [TBL] [Abstract][Full Text] [Related]
24. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity. Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502 [TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy. Shao Y; Luo W; Guo Q; Li X; Zhang Q; Li J Drug Des Devel Ther; 2019; 13():2043-2055. PubMed ID: 31388296 [No Abstract] [Full Text] [Related]
26. Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin. Cho HJ; Yoon IS; Yoon HY; Koo H; Jin YJ; Ko SH; Shim JS; Kim K; Kwon IC; Kim DD Biomaterials; 2012 Feb; 33(4):1190-200. PubMed ID: 22074664 [TBL] [Abstract][Full Text] [Related]
27. Enhanced chemotherapeutic efficacy of the low-dose doxorubicin in breast cancer via nanoparticle delivery system crosslinked hyaluronic acid. Wang Q; Zhong Y; Liu W; Wang Z; Gu L; Li X; Zheng J; Du H; Zhong Z; Xie F Drug Deliv; 2019 Dec; 26(1):12-22. PubMed ID: 30691317 [TBL] [Abstract][Full Text] [Related]
28. Facile strategy by hyaluronic acid functional carbon dot-doxorubicin nanoparticles for CD44 targeted drug delivery and enhanced breast cancer therapy. Li J; Li M; Tian L; Qiu Y; Yu Q; Wang X; Guo R; He Q Int J Pharm; 2020 Mar; 578():119122. PubMed ID: 32035259 [TBL] [Abstract][Full Text] [Related]
29. The effect of dual-functional hyaluronic acid-vitamin E succinate micelles on targeting delivery of doxorubicin. Wang J; Ma W; Guo Q; Li Y; Hu Z; Zhu Z; Wang X; Zhao Y; Chai X; Tu P Int J Nanomedicine; 2016; 11():5851-5870. PubMed ID: 27853369 [TBL] [Abstract][Full Text] [Related]
30. Intracellular self-disassemble polysaccharide nanoassembly for multi-factors tumor drug resistance modulation of doxorubicin. Xiong H; Ni J; Jiang Z; Tian F; Zhou J; Yao J Biomater Sci; 2018 Aug; 6(9):2527-2540. PubMed ID: 30105340 [TBL] [Abstract][Full Text] [Related]
31. NIR and UV-responsive degradable hyaluronic acid nanogels for CD44-targeted and remotely triggered intracellular doxorubicin delivery. Hang C; Zou Y; Zhong Y; Zhong Z; Meng F Colloids Surf B Biointerfaces; 2017 Oct; 158():547-555. PubMed ID: 28743090 [TBL] [Abstract][Full Text] [Related]
32. Combination of doxorubicin with harmine-loaded liposomes exerting synergistic antitumor efficacy. Lei J; Cong S; Song M; Zhang W; Peng G; Li X; Liu Y Drug Dev Ind Pharm; 2018 Apr; 44(4):570-581. PubMed ID: 29260918 [TBL] [Abstract][Full Text] [Related]
33. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model. Moosavian SA; Abnous K; Badiee A; Jaafari MR Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819 [TBL] [Abstract][Full Text] [Related]
34. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion. Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386 [TBL] [Abstract][Full Text] [Related]
35. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy. Li W; Yi X; Liu X; Zhang Z; Fu Y; Gong T J Control Release; 2016 Mar; 225():170-82. PubMed ID: 26826304 [TBL] [Abstract][Full Text] [Related]
36. CD44 Receptor Targeting and Endosomal pH-Sensitive Dual Functional Hyaluronic Acid Micelles for Intracellular Paclitaxel Delivery. Liu Y; Zhou C; Wang W; Yang J; Wang H; Hong W; Huang Y Mol Pharm; 2016 Dec; 13(12):4209-4221. PubMed ID: 27796093 [TBL] [Abstract][Full Text] [Related]
37. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer. Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132 [TBL] [Abstract][Full Text] [Related]
38. Tumor targeting using anti-her2 immunoliposomes. Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487 [TBL] [Abstract][Full Text] [Related]
39. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin. Qiu L; Qiao M; Chen Q; Tian C; Long M; Wang M; Li Z; Hu W; Li G; Cheng L; Cheng L; Hu H; Zhao X; Chen D Biomaterials; 2014 Dec; 35(37):9877-9887. PubMed ID: 25201738 [TBL] [Abstract][Full Text] [Related]
40. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts. Gazzano E; Buondonno I; Marengo A; Rolando B; Chegaev K; Kopecka J; Saponara S; Sorge M; Hattinger CM; Gasco A; Fruttero R; Brancaccio M; Serra M; Stella B; Fattal E; Arpicco S; Riganti C Cancer Lett; 2019 Aug; 456():29-39. PubMed ID: 31047947 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]